Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AstraZeneca pays $35mm up front for rights to Ardelyx's NH3 inhibitors; deal ends

Executive Summary

Ardelyx Inc. (developing therapeutics that target gut transporters and receptors related to cardiovascular, renal, and gastrointestinal diseases) has granted AstraZeneca PLC exclusive global rights to its sodium-hydrogen exchange 3 (NHE3) inhibitor program, including lead compound RDX5791, which is in Phase II trials for complications of end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies